Zeria Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Zeria Pharmaceutical has a total shareholder equity of ¥82.2B and total debt of ¥44.4B, which brings its debt-to-equity ratio to 54%. Its total assets and total liabilities are ¥152.1B and ¥69.9B respectively. Zeria Pharmaceutical's EBIT is ¥10.6B making its interest coverage ratio -182.6. It has cash and short-term investments of ¥19.9B.
Key information
54.0%
Debt to equity ratio
JP¥44.41b
Debt
| Interest coverage ratio | -182.6x |
| Cash | JP¥19.90b |
| Equity | JP¥82.18b |
| Total liabilities | JP¥69.94b |
| Total assets | JP¥152.12b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 4559's short term assets (¥60.5B) exceed its short term liabilities (¥54.6B).
Long Term Liabilities: 4559's short term assets (¥60.5B) exceed its long term liabilities (¥15.4B).
Debt to Equity History and Analysis
Debt Level: 4559's net debt to equity ratio (29.8%) is considered satisfactory.
Reducing Debt: 4559's debt to equity ratio has reduced from 65.3% to 54% over the past 5 years.
Debt Coverage: 4559's debt is well covered by operating cash flow (27.4%).
Interest Coverage: 4559 earns more interest than it pays, so coverage of interest payments is not a concern.